Sarsagenin | PYM-50018 | Myogane | CAS#126-19-2 | Neurotrophic Agent

MedKoo Cat#: 527419 | Name: Sarsagenin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sarsagenin, also known as PYM-50018 and Myogane, is a neurotrophic agent potentially for the treatment of amyotrophic lateral sclerosis (ALS) and glaucoma.

Chemical Structure

Sarsagenin

CAS#126-19-2

Theoretical Analysis

MedKoo Cat#: 527419

Name: Sarsagenin

CAS#: 126-19-2

Chemical Formula: C27H44O3

Exact Mass: 416.3290

Molecular Weight: 416.65

Elemental Analysis: C, 77.84; H, 10.65; O, 11.52

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 190.00
50mg	USD 350.00
100mg	USD 650.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Sarsagenin; PYM-50018; PYM 50018; PYM50018; Myogane; Sarsasapogenin

IUPAC/Chemical Name

(2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol

InChi Key

GMBQZIIUCVWOCD-WWASVFFGSA-N

InChi Code

InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17-,18+,19-,20+,21-,22-,23-,24-,25-,26-,27+/m0/s1

SMILES Code

[H][C@]1(O[C@@]2(OC[C@@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC[C@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Sarsagenin inhibits proliferation of HeLa cervical, MCF-7 breast, HepG2 liver, A549 lung, A375.S2 melanoma, and HT-1080 fibrosarcoma cells (IC50s = 31.36-48.79 μM) and dose-dependently induces apoptosis of HeLa cells.

In vitro activity:

Sarsagenin treatment reduces STIM1 expression, hindering aggressive behaviors in vascular smooth muscle cells exposed to oxidized low-density lipoprotein (ox-LDL). This treatment protects against ox-LDL-induced cell proliferation, migration, and invasion. Sarsagenin also decreases the heightened STIM1 and Orai levels in ox-LDL-treated cells. Importantly, elevated STIM1 partly reverses Sarsagenin’s effects on cell behavior in ox-LDL-challenged cells. Reference: Cardiovasc Diagn Ther. 2023 Jun 30;13(3):441-452. https://pubmed.ncbi.nlm.nih.gov/37405015/

In vivo activity:

The findings of this study suggest that Sarsagenin ameliorates insulin resistance and alleviates the adipose inflammatory state in high-fat diet mice. Sarsagenin may be a potential agent for the treatment of insulin resistance and obesity-related metabolic diseases. Reference: Acta Pharmacol Sin. 2021 Feb;42(2):272-281. https://pubmed.ncbi.nlm.nih.gov/32699264/

	Solvent	mg/mL	mM
Solubility
	DMF	2.0	4.80
	DMSO	0.2	0.48
	Ethanol	2.0	4.80

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 416.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhai H, Liu H, Shang B, Zou X. Sarsasapogenin blocks ox-LDL-stimulated vascular smooth muscle cell proliferation, migration, and invasion through suppressing STIM1 expression. Cardiovasc Diagn Ther. 2023 Jun 30;13(3):441-452. doi: 10.21037/cdt-23-111. Epub 2023 Jun 2. PMID: 37405015; PMCID: PMC10315424. 2. Wang W, Wang D, Wang Z, Yao G, Li X, Gao P, Li L, Zhang Y, Wang S, Song S. Synthesis of new sarsasapogenin derivatives with cytotoxicity and apoptosis-inducing activities in human breast cancer MCF-7 cells. Eur J Med Chem. 2017 Feb 15;127:62-71. doi: 10.1016/j.ejmech.2016.12.011. Epub 2016 Dec 20. PMID: 28038327. 3. Kong L, Liu Y, Zhang YM, Li Y, Gou LS, Ma TF, Liu YW. Sarsasapogenin ameliorates diabetes-associated memory impairment and neuroinflammation through down-regulation of PAR-1 receptor. Phytother Res. 2021 Jun;35(6):3167-3180. doi: 10.1002/ptr.7005. Epub 2021 Apr 22. PMID: 33885189. 4. Yu YY, Cui SC, Zheng TN, Ma HJ, Xie ZF, Jiang HW, Li YF, Zhu KX, Huang CG, Li J, Li JY. Sarsasapogenin improves adipose tissue inflammation and ameliorates insulin resistance in high-fat diet-fed C57BL/6J mice. Acta Pharmacol Sin. 2021 Feb;42(2):272-281. doi: 10.1038/s41401-020-0427-1. Epub 2020 Jul 22. PMID: 32699264; PMCID: PMC8027656.

In vitro protocol:

In vivo protocol:

1. Kong L, Liu Y, Zhang YM, Li Y, Gou LS, Ma TF, Liu YW. Sarsasapogenin ameliorates diabetes-associated memory impairment and neuroinflammation through down-regulation of PAR-1 receptor. Phytother Res. 2021 Jun;35(6):3167-3180. doi: 10.1002/ptr.7005. Epub 2021 Apr 22. PMID: 33885189. 2. Yu YY, Cui SC, Zheng TN, Ma HJ, Xie ZF, Jiang HW, Li YF, Zhu KX, Huang CG, Li J, Li JY. Sarsasapogenin improves adipose tissue inflammation and ameliorates insulin resistance in high-fat diet-fed C57BL/6J mice. Acta Pharmacol Sin. 2021 Feb;42(2):272-281. doi: 10.1038/s41401-020-0427-1. Epub 2020 Jul 22. PMID: 32699264; PMCID: PMC8027656.

1: Harvey A. Natural Products in Drug Discovery and Development. 27-28 June 2005, London, UK. IDrugs. 2005 Sep;8(9):719-21. PubMed PMID: 16118691.